首页 > 最新文献

Integrated Blood Pressure Control最新文献

英文 中文
Effectiveness of continuous positive airway pressure in lowering blood pressure in patients with obstructive sleep apnea: a critical review of the literature 持续气道正压对降低阻塞性睡眠呼吸暂停患者血压的有效性:文献综述
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2016-03-15 DOI: 10.2147/IBPC.S70402
Fernanda Fatureto-Borges, G. Lorenzi-Filho, L. Drager
Obstructive sleep apnea (OSA) is an extremely common comorbid condition in patients with hypertension, with a prevalence of ~50%. There is growing evidence suggesting that OSA is a secondary cause of hypertension, associated with both poor blood pressure (BP) control and target organ damage in patients with hypertension. The application of continuous positive airway pressure (CPAP) during sleep is the gold standard treatment of moderate- to-severe OSA and very effective in abolishing obstructive respiratory events. However, several meta-analyses showed that the overall impact of CPAP on BP is modest (~2 mmHg). There are several potential reasons for this disappointing finding, including the heterogeneity of patients studied (normotensive patients, controlled, and uncontrolled patients with hypertension), non-ideal CPAP compliance, clinical presentation (there is some evidence that the positive impact of CPAP on lowering BP is more evident in sleepy patients), and the multifactorial nature of hypertension. In this review, we performed a critical analysis of the literature evaluating the impact of CPAP on BP in several subgroups of patients. We finally discussed perspectives in this important research area, including the urgent need to identify predictors of BP response to CPAP and the importance of precision medicine in this scenario.
阻塞性睡眠呼吸暂停(OSA)是高血压患者极为常见的合并症,患病率约为50%。越来越多的证据表明,OSA是高血压的继发原因,与高血压患者血压控制不佳和靶器官损害有关。睡眠期间应用持续气道正压通气(CPAP)是中重度OSA的金标准治疗方法,对消除阻塞性呼吸事件非常有效。然而,一些荟萃分析显示,CPAP对血压的总体影响是适度的(~2 mmHg)。这一令人失望的发现有几个潜在的原因,包括研究患者的异质性(血压正常的患者,控制和不控制的高血压患者),不理想的CPAP依从性,临床表现(有证据表明CPAP对降低血压的积极影响在困倦的患者中更为明显),以及高血压的多因素性质。在这篇综述中,我们对评估CPAP对几个亚组患者血压影响的文献进行了批判性分析。我们最后讨论了这一重要研究领域的观点,包括迫切需要确定CPAP对BP反应的预测因素以及精准医学在这一情况下的重要性。
{"title":"Effectiveness of continuous positive airway pressure in lowering blood pressure in patients with obstructive sleep apnea: a critical review of the literature","authors":"Fernanda Fatureto-Borges, G. Lorenzi-Filho, L. Drager","doi":"10.2147/IBPC.S70402","DOIUrl":"https://doi.org/10.2147/IBPC.S70402","url":null,"abstract":"Obstructive sleep apnea (OSA) is an extremely common comorbid condition in patients with hypertension, with a prevalence of ~50%. There is growing evidence suggesting that OSA is a secondary cause of hypertension, associated with both poor blood pressure (BP) control and target organ damage in patients with hypertension. The application of continuous positive airway pressure (CPAP) during sleep is the gold standard treatment of moderate- to-severe OSA and very effective in abolishing obstructive respiratory events. However, several meta-analyses showed that the overall impact of CPAP on BP is modest (~2 mmHg). There are several potential reasons for this disappointing finding, including the heterogeneity of patients studied (normotensive patients, controlled, and uncontrolled patients with hypertension), non-ideal CPAP compliance, clinical presentation (there is some evidence that the positive impact of CPAP on lowering BP is more evident in sleepy patients), and the multifactorial nature of hypertension. In this review, we performed a critical analysis of the literature evaluating the impact of CPAP on BP in several subgroups of patients. We finally discussed perspectives in this important research area, including the urgent need to identify predictors of BP response to CPAP and the importance of precision medicine in this scenario.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"43 - 47"},"PeriodicalIF":2.2,"publicationDate":"2016-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S70402","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
Probiotics and blood pressure: current insights 益生菌和血压:最新的见解
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2016-02-25 DOI: 10.2147/IBPC.S73246
Aditya Upadrasta, R. Madempudi
Gut microbiota play a significant role in host metabolic processes, and recent metagenomic surveys have revealed that they are involved in host immune modulation and influence host development and physiology (organ development). Initially, probiotics are identified as potential therapeutics to treat gastrointestinal disorders and to revitalize the disturbed gut ecosystem. Currently, studies are exploring the potential for expanded uses of probiotics for improving the health conditions in metabolic disorders that increase the risk of developing cardiovascular diseases such as hypertension. Further investigations are required to evaluate targeted and effective use of the wide variety of probiotic strains in various metabolic disorders to improve the overall health status of the host. This review addresses the causes of hypertension and the hypotensive effect of probiotics, with a focus on their mechanistic action.
肠道微生物群在宿主代谢过程中发挥着重要作用,最近的宏基因组研究表明它们参与宿主免疫调节并影响宿主发育和生理(器官发育)。最初,益生菌被认为是治疗胃肠道疾病和恢复紊乱肠道生态系统的潜在疗法。目前,研究正在探索扩大使用益生菌的潜力,以改善代谢紊乱的健康状况,增加患心血管疾病(如高血压)的风险。需要进一步的研究来评估在各种代谢紊乱中有针对性和有效地使用各种益生菌菌株以改善宿主的整体健康状况。本文综述了高血压的原因和益生菌的降压作用,重点介绍了它们的机制作用。
{"title":"Probiotics and blood pressure: current insights","authors":"Aditya Upadrasta, R. Madempudi","doi":"10.2147/IBPC.S73246","DOIUrl":"https://doi.org/10.2147/IBPC.S73246","url":null,"abstract":"Gut microbiota play a significant role in host metabolic processes, and recent metagenomic surveys have revealed that they are involved in host immune modulation and influence host development and physiology (organ development). Initially, probiotics are identified as potential therapeutics to treat gastrointestinal disorders and to revitalize the disturbed gut ecosystem. Currently, studies are exploring the potential for expanded uses of probiotics for improving the health conditions in metabolic disorders that increase the risk of developing cardiovascular diseases such as hypertension. Further investigations are required to evaluate targeted and effective use of the wide variety of probiotic strains in various metabolic disorders to improve the overall health status of the host. This review addresses the causes of hypertension and the hypotensive effect of probiotics, with a focus on their mechanistic action.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"33 - 42"},"PeriodicalIF":2.2,"publicationDate":"2016-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S73246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 56
Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model. 慢性白藜芦醇在大鼠模型中逆转轻度血管紧张素ii诱导的降压作用。
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2016-01-28 eCollection Date: 2016-01-01 DOI: 10.2147/IBPC.S96092
Kevin L Gordish, William H Beierwaltes

Resveratrol is reported to reduce blood pressure in animal models of hypertension, but the mechanisms are unknown. We have shown that resveratrol infusion increases sodium excretion. We hypothesized that chronic ingestion of resveratrol would reduce angiotensin II (Ang II)-induced increases in blood pressure by decreasing oxidative stress and by also decreasing sodium reabsorption through a nitric oxide-dependent mechanism. We infused rats with vehicle or 80 μg Ang II/d over 4 weeks. Vehicle or Ang II-infused rats were individually housed, pair fed, and placed on a diet of normal chow or normal chow plus 146 mg resveratrol/d. Groups included 1) control, 2) resveratrol-fed, 3) Ang II-treated, and 4) Ang II plus resveratrol. Systolic blood pressure was measured by tail cuff. During the 4th week, rats were placed in metabolic caging for urine collection. NO2/NO3 and 8-isoprostane excretion were measured. Ang II increased systolic blood pressure in the 1st week by +14±5 mmHg (P<0.05) in Group 3 and +10±3 mmHg (P<0.05) in Group 4, respectively. Blood pressure was unchanged in Groups 1 and 2. After 4 weeks, blood pressure remained elevated in Group 3 rats with Ang II (+9±3 mmHg, P<0.05), but in Group 4, blood pressure was no longer elevated (+2±2 mmHg). We found no significant differences between the groups in sodium excretion or cumulative sodium balance (18.49±0.12, 17.75±0.16, 17.97±0.17, 18.46±0.18 μEq Na+/7 d in Groups 1-4, respectively). Urinary excretion of NO2/NO3 in the four groups was 1) 1631±207 μmol/24 h, 2) 1045±236 μmol/24 h, 3) 1490±161 μmol/24 h, and 4) 609±17 μmol/24 h. 8-Isoprostane excretion was 1) 63.85±19.39 nmol/24 h, 2) 73.57±22.02 nmol/24 h, 3) 100.69±37.62 nmol/24 h, and 4) 103.00±38.88 nmol/24 h. We conclude that chronic resveratrol supplementation does not blunt Ang II-increased blood pressure, and while resveratrol has mild depressor effects, these do not seem to be due to natriuresis or enhanced renal nitric oxide synthesis.

据报道,白藜芦醇可以降低高血压动物模型的血压,但其机制尚不清楚。我们已经证明白藜芦醇输注会增加钠的排泄。我们假设慢性摄入白藜芦醇可以通过减少氧化应激和通过一氧化氮依赖机制减少钠重吸收来降低血管紧张素II (Ang II)诱导的血压升高。给大鼠灌胃80 μg Ang II/d,持续4周。对照大鼠或注射了angii的大鼠单独饲养,成对饲养,分别饲喂正常饲料或正常饲料加146 mg白藜芦醇/d的饮食。各组包括:1)对照组,2)白藜芦醇组,3)angii组,4)angii加白藜芦醇组。用尾袖测量收缩压。第4周,将大鼠置于代谢笼中收集尿液。测定NO2/NO3和8-异前列腺素排泄量。Angⅱ使第1周收缩压升高+14±5 mmHg (P
{"title":"Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model.","authors":"Kevin L Gordish, William H Beierwaltes","doi":"10.2147/IBPC.S96092","DOIUrl":"10.2147/IBPC.S96092","url":null,"abstract":"<p><p>Resveratrol is reported to reduce blood pressure in animal models of hypertension, but the mechanisms are unknown. We have shown that resveratrol infusion increases sodium excretion. We hypothesized that chronic ingestion of resveratrol would reduce angiotensin II (Ang II)-induced increases in blood pressure by decreasing oxidative stress and by also decreasing sodium reabsorption through a nitric oxide-dependent mechanism. We infused rats with vehicle or 80 μg Ang II/d over 4 weeks. Vehicle or Ang II-infused rats were individually housed, pair fed, and placed on a diet of normal chow or normal chow plus 146 mg resveratrol/d. Groups included 1) control, 2) resveratrol-fed, 3) Ang II-treated, and 4) Ang II plus resveratrol. Systolic blood pressure was measured by tail cuff. During the 4th week, rats were placed in metabolic caging for urine collection. NO2/NO3 and 8-isoprostane excretion were measured. Ang II increased systolic blood pressure in the 1st week by +14±5 mmHg (P<0.05) in Group 3 and +10±3 mmHg (P<0.05) in Group 4, respectively. Blood pressure was unchanged in Groups 1 and 2. After 4 weeks, blood pressure remained elevated in Group 3 rats with Ang II (+9±3 mmHg, P<0.05), but in Group 4, blood pressure was no longer elevated (+2±2 mmHg). We found no significant differences between the groups in sodium excretion or cumulative sodium balance (18.49±0.12, 17.75±0.16, 17.97±0.17, 18.46±0.18 μEq Na+/7 d in Groups 1-4, respectively). Urinary excretion of NO2/NO3 in the four groups was 1) 1631±207 μmol/24 h, 2) 1045±236 μmol/24 h, 3) 1490±161 μmol/24 h, and 4) 609±17 μmol/24 h. 8-Isoprostane excretion was 1) 63.85±19.39 nmol/24 h, 2) 73.57±22.02 nmol/24 h, 3) 100.69±37.62 nmol/24 h, and 4) 103.00±38.88 nmol/24 h. We conclude that chronic resveratrol supplementation does not blunt Ang II-increased blood pressure, and while resveratrol has mild depressor effects, these do not seem to be due to natriuresis or enhanced renal nitric oxide synthesis. </p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"23-31"},"PeriodicalIF":2.2,"publicationDate":"2016-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S96092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial 老化大蒜提取物对未控制高血压患者血压和其他心血管危险因素的影响:AGE at Heart试验
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2016-01-27 DOI: 10.2147/IBPC.S93335
K. Ried, N. Travica, A. Sali
Background Hypertension affects 30% of adults worldwide. Garlic supplements have shown promise in the treatment of uncontrolled hypertension, and the mechanism of action is biologically plausible. Our trial is the first to assess the effect of aged garlic extract on central blood pressure and arterial stiffness, regarded as important risk factors for cardiovascular morbidity. Subjects and methods A total of 88 general practice patients and community members with uncontrolled hypertension completed a double-blind randomized placebo-controlled trial of 12 weeks investigating the effect of daily intake of aged garlic extract (1.2 g containing 1.2 mg S-allylcysteine) or placebo on blood pressure, and secondary outcome measures of central-hemodynamics and other cardiovascular markers, including cholesterol, homocysteine, platelet function, and inflammatory markers. Results Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P<0.001). Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness. While changes in other cardiovascular markers did not reach significance due to small numbers in subgroups with elevated levels, trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed. Aged garlic extract was highly tolerable and acceptable, and did not increase the risk of bleeding in patients on blood-thinning medication. Conclusion Our trial suggests that aged garlic extract is effective in reducing peripheral and central blood pressure in a large proportion of patients with uncontrolled hypertension, and has the potential to improve arterial stiffness, inflammation, and other cardiovascular markers in patients with elevated levels. Aged garlic extract was highly tolerable with a high safety profile as a stand-alone or adjunctive antihypertensive treatment.
背景:全世界有30%的成年人患有高血压。大蒜补充剂在治疗不受控制的高血压方面显示出希望,其作用机制在生物学上是合理的。我们的试验首次评估了陈年大蒜提取物对中心血压和动脉僵硬的影响,这两项被认为是心血管疾病的重要危险因素。研究对象和方法共有88名高血压患者和社区成员完成了一项为期12周的双盲随机安慰剂对照试验,研究了每天摄入陈化大蒜提取物(1.2 g含1.2 mg s -丙氨酸半胱氨酸)或安慰剂对血压的影响,以及中央血流动力学和其他心血管标志物的次要结局指标,包括胆固醇、同型半胱氨酸、血小板功能和炎症标志物。结果与安慰剂组相比,患者平均收缩压显著降低5.0±2.1 mmHg (P=0.016),缓解组收缩压显著降低11.5±1.9 mmHg,舒张压显著降低6.3±1.1 mmHg (P<0.001)。与安慰剂组相比,大蒜组的中心血流动力学指标有改善的趋势,包括中心血压、中心脉压、平均动脉压、增压压、脉搏波速度和动脉僵硬度。虽然其他心血管标志物的变化没有达到显著性,因为少数亚组的水平升高,大蒜对炎症标志物TNFα,总胆固醇,低密度脂质胆固醇和载脂蛋白的有益影响趋势被观察到。陈年大蒜提取物具有高度的耐受性和可接受性,并且不会增加服用血液稀释药物的患者出血的风险。结论我们的试验表明,陈年大蒜提取物可以有效降低大部分未控制高血压患者的外周血和中枢血压,并有可能改善高血压患者的动脉僵硬、炎症和其他心血管指标。陈年大蒜提取物作为独立或辅助抗高血压治疗具有高度耐受性和高安全性。
{"title":"The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial","authors":"K. Ried, N. Travica, A. Sali","doi":"10.2147/IBPC.S93335","DOIUrl":"https://doi.org/10.2147/IBPC.S93335","url":null,"abstract":"Background Hypertension affects 30% of adults worldwide. Garlic supplements have shown promise in the treatment of uncontrolled hypertension, and the mechanism of action is biologically plausible. Our trial is the first to assess the effect of aged garlic extract on central blood pressure and arterial stiffness, regarded as important risk factors for cardiovascular morbidity. Subjects and methods A total of 88 general practice patients and community members with uncontrolled hypertension completed a double-blind randomized placebo-controlled trial of 12 weeks investigating the effect of daily intake of aged garlic extract (1.2 g containing 1.2 mg S-allylcysteine) or placebo on blood pressure, and secondary outcome measures of central-hemodynamics and other cardiovascular markers, including cholesterol, homocysteine, platelet function, and inflammatory markers. Results Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P<0.001). Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness. While changes in other cardiovascular markers did not reach significance due to small numbers in subgroups with elevated levels, trends in beneficial effects of garlic on the inflammatory markers TNFα, total cholesterol, low-density lipid cholesterol, and apolipoproteins were observed. Aged garlic extract was highly tolerable and acceptable, and did not increase the risk of bleeding in patients on blood-thinning medication. Conclusion Our trial suggests that aged garlic extract is effective in reducing peripheral and central blood pressure in a large proportion of patients with uncontrolled hypertension, and has the potential to improve arterial stiffness, inflammation, and other cardiovascular markers in patients with elevated levels. Aged garlic extract was highly tolerable with a high safety profile as a stand-alone or adjunctive antihypertensive treatment.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"9 - 21"},"PeriodicalIF":2.2,"publicationDate":"2016-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S93335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 89
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension 缓释口服曲前列地尼治疗肺动脉高压的临床应用
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2016-01-25 DOI: 10.2147/IBPC.S68230
S. Pugliese, T. Bull
The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil’s current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.
前列环素肠外治疗的发展标志着肺动脉高压(PAH)治疗的重大突破。静脉注射(IV)丙烯醇是PAH的第一种特异性治疗方法,迄今为止,也是唯一一种证明降低死亡率的治疗方法。由于持续静脉输注治疗患者固有的复杂性和风险,人们对开发一种口服前列环素类似物产生了极大的兴趣,这种类似物可以模仿静脉输注治疗的益处。在此,我们强调口服前列环素治疗的发展,重点是口服曲前列素,这是美国食品和药物管理局唯一批准的口服前列环素。最近的III期临床试验表明,该药可以改善treatment-naïve PAH患者的运动耐受性,但对口服治疗的患者无效。口服曲前列替尼在高剂量时似乎最有效,但其副作用和剂量复杂性使其使用复杂化。虽然口服曲前列尼目前在多环芳烃中的治疗作用尚不清楚,但对这类药物的持续研究应有助于阐明其在治疗多环芳烃中的作用。
{"title":"Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension","authors":"S. Pugliese, T. Bull","doi":"10.2147/IBPC.S68230","DOIUrl":"https://doi.org/10.2147/IBPC.S68230","url":null,"abstract":"The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil’s current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"1 - 7"},"PeriodicalIF":2.2,"publicationDate":"2016-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S68230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Renal denervation for the management of resistant hypertension 肾去神经支配治疗顽固性高血压
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2015-12-03 DOI: 10.2147/IBPC.S65632
H. Patel, C. Hayward, V. Vassiliou, Ketna S Patel, J. Howard, C. Di Mario
Renal sympathetic denervation (RSD) as a therapy for patients with resistant hypertension has attracted great interest. The majority of studies in this field have demonstrated impressive reductions in blood pressure (BP). However, these trials were not randomized or sham-controlled and hence, the findings may have been overinflated due to trial biases. SYMPLICITY HTN-3 was the first randomized controlled trial to use a blinded sham-control and ambulatory BP monitoring. A surprise to many was that this study was neutral. Possible reasons for this neutrality include the fact that RSD may not be effective at lowering BP in man, RSD was not performed adequately due to limited operator experience, patients’ adherence with their anti-hypertensive drugs may have changed during the trial period, and perhaps the intervention only works in certain subgroups that are yet to be identified. Future studies seeking to demonstrate efficacy of RSD should be designed as randomized blinded sham-controlled trials. The efficacy of RSD is in doubt, but many feel that its safety has been established through the thousands of patients in whom the procedure has been performed. Over 90% of these data, however, are for the Symplicity™ system and rarely extend beyond 12 months of follow-up. Long-term safety cannot be assumed with RSD and nor should it be assumed that if one catheter system is safe then all are. We hope that in the near future, with the benefit of well-designed clinical trials, the role of renal denervation in the management of hypertension will be established.
肾交感神经去支配作为一种治疗顽固性高血压的方法引起了人们的广泛关注。这一领域的大多数研究表明,它能显著降低血压(BP)。然而,这些试验不是随机的或假对照的,因此,由于试验偏差,研究结果可能被夸大了。HTN-3是第一个使用盲法假对照和动态血压监测的随机对照试验。令许多人惊讶的是,这项研究是中立的。这种中立性的可能原因包括:RSD可能对男性降压无效,由于操作者经验有限,RSD没有得到充分的执行,患者对抗高血压药物的依从性可能在试验期间发生了变化,可能干预只对某些尚未确定的亚组有效。未来旨在证明RSD疗效的研究应设计为随机盲法假对照试验。RSD的有效性尚存疑问,但许多人认为,通过对数千名患者实施该手术,其安全性已经得到了证实。然而,超过90%的这些数据是针对Symplicity™系统的,很少超过12个月的随访。不能假设RSD是长期安全的,也不应该假设如果一个导管系统是安全的,那么所有的都是安全的。我们希望在不久的将来,通过精心设计的临床试验,肾去神经支配在高血压治疗中的作用将被确立。
{"title":"Renal denervation for the management of resistant hypertension","authors":"H. Patel, C. Hayward, V. Vassiliou, Ketna S Patel, J. Howard, C. Di Mario","doi":"10.2147/IBPC.S65632","DOIUrl":"https://doi.org/10.2147/IBPC.S65632","url":null,"abstract":"Renal sympathetic denervation (RSD) as a therapy for patients with resistant hypertension has attracted great interest. The majority of studies in this field have demonstrated impressive reductions in blood pressure (BP). However, these trials were not randomized or sham-controlled and hence, the findings may have been overinflated due to trial biases. SYMPLICITY HTN-3 was the first randomized controlled trial to use a blinded sham-control and ambulatory BP monitoring. A surprise to many was that this study was neutral. Possible reasons for this neutrality include the fact that RSD may not be effective at lowering BP in man, RSD was not performed adequately due to limited operator experience, patients’ adherence with their anti-hypertensive drugs may have changed during the trial period, and perhaps the intervention only works in certain subgroups that are yet to be identified. Future studies seeking to demonstrate efficacy of RSD should be designed as randomized blinded sham-controlled trials. The efficacy of RSD is in doubt, but many feel that its safety has been established through the thousands of patients in whom the procedure has been performed. Over 90% of these data, however, are for the Symplicity™ system and rarely extend beyond 12 months of follow-up. Long-term safety cannot be assumed with RSD and nor should it be assumed that if one catheter system is safe then all are. We hope that in the near future, with the benefit of well-designed clinical trials, the role of renal denervation in the management of hypertension will be established.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"8 1","pages":"57 - 69"},"PeriodicalIF":2.2,"publicationDate":"2015-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S65632","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68363119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Comparison between treadmill and bicycle ergometer exercise tests in mild-to-moderate hypertensive Nigerians. 轻度至中度高血压尼日利亚人的跑步机和自行车测力计运动测试比较。
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2015-08-11 eCollection Date: 2015-01-01 DOI: 10.2147/IBPC.S75888
Olugbenga O Abiodun, Michael O Balogun, Anthony O Akintomide, Rasaaq A Adebayo, Olufemi E Ajayi, Suraj A Ogunyemi, Valentine N Amadi, Victor O Adeyeye

Background: Comparative cardiovascular responses to treadmill and bicycle ergometer (bike) exercise tests in hypertensive Nigerians are not known. This study compared cardiovascular responses to the two modes of exercise testing in hypertensives using maximal exercise protocols.

Methods: One hundred and ten male subjects with mild-to-moderate hypertension underwent maximal treadmill and bike test one after the other at a single visit in a simple random manner. Paired-sampled t-test was used to compare responses to both exercise tests while chi-squared test was used to compare categorical variables.

Results: The maximal heart rate (P<0.001), peak systolic blood pressure (P=0.02), rate pressure product (P<0.001), peak oxygen uptake (P<0.001), and exercise capacity (P<0.001) in metabolic equivalents were signifcantly higher on the treadmill than on the bike.

Conclusion: Higher cardiovascular responses on treadmill in Nigerian male hypertensives in this study, similar to findings in non-hypertensives and non-Nigerians in earlier studies, suggest that treadmill may be of better diagnostic utility in our population.

背景:尼日利亚高血压患者对跑步机和自行车测力计(自行车)运动测试的心血管反应比较尚不清楚。本研究采用最大运动方案,比较了高血压患者对两种运动测试模式的心血管反应:方法:110 名患有轻度至中度高血压的男性受试者在一次就诊中以简单随机的方式先后接受了最大跑步机和自行车测试。采用配对抽样 t 检验比较两种运动测试的反应,采用卡方检验比较分类变量:结果:最大心率(PConclusion:本研究中,尼日利亚男性高血压患者在跑步机上的心血管反应较高,这与早期研究中对非高血压患者和非尼日利亚人的研究结果相似,表明跑步机在我国人群中可能具有更好的诊断效用。
{"title":"Comparison between treadmill and bicycle ergometer exercise tests in mild-to-moderate hypertensive Nigerians.","authors":"Olugbenga O Abiodun, Michael O Balogun, Anthony O Akintomide, Rasaaq A Adebayo, Olufemi E Ajayi, Suraj A Ogunyemi, Valentine N Amadi, Victor O Adeyeye","doi":"10.2147/IBPC.S75888","DOIUrl":"10.2147/IBPC.S75888","url":null,"abstract":"<p><strong>Background: </strong>Comparative cardiovascular responses to treadmill and bicycle ergometer (bike) exercise tests in hypertensive Nigerians are not known. This study compared cardiovascular responses to the two modes of exercise testing in hypertensives using maximal exercise protocols.</p><p><strong>Methods: </strong>One hundred and ten male subjects with mild-to-moderate hypertension underwent maximal treadmill and bike test one after the other at a single visit in a simple random manner. Paired-sampled t-test was used to compare responses to both exercise tests while chi-squared test was used to compare categorical variables.</p><p><strong>Results: </strong>The maximal heart rate (P<0.001), peak systolic blood pressure (P=0.02), rate pressure product (P<0.001), peak oxygen uptake (P<0.001), and exercise capacity (P<0.001) in metabolic equivalents were signifcantly higher on the treadmill than on the bike.</p><p><strong>Conclusion: </strong>Higher cardiovascular responses on treadmill in Nigerian male hypertensives in this study, similar to findings in non-hypertensives and non-Nigerians in earlier studies, suggest that treadmill may be of better diagnostic utility in our population.</p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"8 ","pages":"51-5"},"PeriodicalIF":2.2,"publicationDate":"2015-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/74/ibpc-8-051.PMC4540160.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34026182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes. 家庭血压监测能改善病人的预后吗?比较家庭和动态血压监测对血压控制和患者预后的系统综述。
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2015-07-03 eCollection Date: 2015-01-01 DOI: 10.2147/IBPC.S49205
Tonya L Breaux-Shropshire, Eric Judd, Lee A Vucovich, Toneyell S Shropshire, Sonal Singh

Objective: Our objective was to compare the clinical effectiveness of home blood pressure monitoring (HBPM) and 24-hour ambulatory blood pressure monitoring (ABPM) on blood pressure (BP) control and patient outcomes.

Design: A systematic review was conducted. We also appraised the methodological quality of studies.

Data sources: PubMed, Scopus, CINAHL, and the Cochrane Central Register of Control Trials (CENTRAL).

Inclusion criteria: Randomized control trials, prospective and retrospective cohort studies, observational studies, and case-control studies published in English from any year to present that describe HBPM and 24-hour ABPM and report on systolic and/or diastolic BP and/or heart attack, stroke, kidney failure and/or all-cause mortality for adult patients. Due to the nature of the question, studies with only untreated patients were not considered.

Results: Of 1,742 titles and abstractions independently reviewed by two reviewers, 137 studies met predetermined criteria for evaluation. Nineteen studies were identified as relevant and included in the paper. The common themes were that HBPM and ABPM correlated with cardiovascular events and mortality, and targeting HBPM or ABPM resulted in similar outcomes. Associations between BP measurement type and mortality differed by study population. Both the low sensitivity of office blood pressure monitoring (OBPM) to detect optimal BP control by ABPM and the added association of HBPM with cardiovascular mortality supported the routine use of HBPM in clinical practice. There was insufficient data to determine the benefit of using HBPM as a measurement standard for BP control.

Conclusion: HBPM encourages patient-centered care and improves BP control and patient outcomes. Given the limited number of studies with both HBPM and ABPM, these measurement types should be incorporated into the design of randomized clinical trials within hypertensive populations.

目的:我们的目的是比较家庭血压监测(HBPM)和24小时动态血压监测(ABPM)在血压控制和患者预后方面的临床效果。设计:进行系统评价。我们还评估了研究的方法学质量。数据来源:PubMed, Scopus, CINAHL, Cochrane Central Register of Control Trials (Central)。纳入标准:随机对照试验,前瞻性和回顾性队列研究,观察性研究,以及从任何年份至今发表的英文病例对照研究,这些研究描述了HBPM和24小时ABPM,并报告了收缩压和/或舒张压和/或心脏病发作,中风,肾衰竭和/或全因死亡率。由于问题的性质,未考虑仅对未经治疗的患者进行研究。结果:在两位审稿人独立评审的1742篇标题和摘要中,有137篇研究符合预定的评价标准。19项研究被确定为相关并纳入论文。共同的主题是HBPM和ABPM与心血管事件和死亡率相关,靶向HBPM或ABPM导致相似的结果。血压测量类型与死亡率之间的关系因研究人群而异。办公室血压监测(OBPM)通过ABPM检测最佳血压控制的低灵敏度以及HBPM与心血管死亡率的附加关联都支持HBPM在临床实践中的常规使用。没有足够的数据来确定使用HBPM作为血压控制的测量标准的好处。结论:HBPM鼓励以患者为中心的护理,改善血压控制和患者预后。鉴于HBPM和ABPM的研究数量有限,这些测量类型应纳入高血压人群随机临床试验的设计中。
{"title":"Does home blood pressure monitoring improve patient outcomes? A systematic review comparing home and ambulatory blood pressure monitoring on blood pressure control and patient outcomes.","authors":"Tonya L Breaux-Shropshire,&nbsp;Eric Judd,&nbsp;Lee A Vucovich,&nbsp;Toneyell S Shropshire,&nbsp;Sonal Singh","doi":"10.2147/IBPC.S49205","DOIUrl":"https://doi.org/10.2147/IBPC.S49205","url":null,"abstract":"<p><strong>Objective: </strong>Our objective was to compare the clinical effectiveness of home blood pressure monitoring (HBPM) and 24-hour ambulatory blood pressure monitoring (ABPM) on blood pressure (BP) control and patient outcomes.</p><p><strong>Design: </strong>A systematic review was conducted. We also appraised the methodological quality of studies.</p><p><strong>Data sources: </strong>PubMed, Scopus, CINAHL, and the Cochrane Central Register of Control Trials (CENTRAL).</p><p><strong>Inclusion criteria: </strong>Randomized control trials, prospective and retrospective cohort studies, observational studies, and case-control studies published in English from any year to present that describe HBPM and 24-hour ABPM and report on systolic and/or diastolic BP and/or heart attack, stroke, kidney failure and/or all-cause mortality for adult patients. Due to the nature of the question, studies with only untreated patients were not considered.</p><p><strong>Results: </strong>Of 1,742 titles and abstractions independently reviewed by two reviewers, 137 studies met predetermined criteria for evaluation. Nineteen studies were identified as relevant and included in the paper. The common themes were that HBPM and ABPM correlated with cardiovascular events and mortality, and targeting HBPM or ABPM resulted in similar outcomes. Associations between BP measurement type and mortality differed by study population. Both the low sensitivity of office blood pressure monitoring (OBPM) to detect optimal BP control by ABPM and the added association of HBPM with cardiovascular mortality supported the routine use of HBPM in clinical practice. There was insufficient data to determine the benefit of using HBPM as a measurement standard for BP control.</p><p><strong>Conclusion: </strong>HBPM encourages patient-centered care and improves BP control and patient outcomes. Given the limited number of studies with both HBPM and ABPM, these measurement types should be incorporated into the design of randomized clinical trials within hypertensive populations.</p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"8 ","pages":"43-9"},"PeriodicalIF":2.2,"publicationDate":"2015-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S49205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33901070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
Vasomotor sympathetic outflow in the muscle metaboreflex in low birth weight young adults. 低出生体重年轻人肌肉代谢反射中的血管舒缩性交感神经流出。
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2015-05-27 eCollection Date: 2015-01-01 DOI: 10.2147/IBPC.S76382
Jephat Chifamba, Brilliant Mbangani, Casper Chimhete, Lenon Gwaunza, Larry A Allen, Herbert Mapfumo Chinyanga

A growing body of evidence suggests that low birth weight (LBW) offspring are associated with long-term structural and functional changes in cardiovascular and neuroendocrine systems. We tested the hypothesis that muscle metaboreflex activation produces exaggerated responses in cardiac autonomic tone (represented by heart rate variability ratio) and cutaneous vascular sympathetic tone (represented by plethysmography pulse wave amplitude) in LBW compared to normal birth weight (NBW) young adults. We recruited 23 LBW (18 females and five males) and 23 NBW (14 females and nine males) University of Zimbabwe students with neonatal clinical cards as proof of birth weight at term. Resting electrocardiogram, pulse waves, and blood pressures were recorded. Participants then underwent a static/isometric handgrip exercise until fatigue and a post-exercise circulatory arrest period of 2 minutes. We observed (results mean ± standard deviation) a greater mean increase in heart rate variability ratio from baseline to exercise for LBW compared to NBW individuals (1.015±1.034 versus [vs] 0.119±0.789, respectively; P<0.05). We also observed a greater mean decrease in plethysmography pulse wave amplitude from baseline to exercise (-1.32±1.064 vs -0.735±0.63; P<0.05) and from baseline to post-exercise circulatory arrest (-0.932±0.998 vs -0.389±0.563; P<0.05) for LBW compared to NBW individuals. We conclude that LBW may be associated with an exaggerated sympathetic discharge in response to muscle metaboreflex.

越来越多的证据表明,低出生体重(LBW)后代与心血管和神经内分泌系统的长期结构和功能变化有关。我们测试了与正常出生体重(NBW)的年轻人相比,肌肉代谢反射激活对LBW的心脏自主神经张力(以心率变异性比率表示)和皮肤血管交感神经张力(以体积脉搏波振幅表示)产生夸大反应的假设。我们招募了23名LBW(18名女性和5名男性)和23名NBW(14名女性和9名男性)的津巴布韦大学学生,他们都有新生儿临床卡作为足月出生体重的证明。静息心电图、脉搏波和血压记录。然后,参与者进行静态/等距握力训练,直到疲劳和运动后2分钟的循环停止期。我们观察到(结果平均值±标准差)与NBW个体相比,LBW个体从基线到运动时心率变异性比的平均增加更大(分别为1.015±1.034和[vs] 0.119±0.789;P
{"title":"Vasomotor sympathetic outflow in the muscle metaboreflex in low birth weight young adults.","authors":"Jephat Chifamba,&nbsp;Brilliant Mbangani,&nbsp;Casper Chimhete,&nbsp;Lenon Gwaunza,&nbsp;Larry A Allen,&nbsp;Herbert Mapfumo Chinyanga","doi":"10.2147/IBPC.S76382","DOIUrl":"https://doi.org/10.2147/IBPC.S76382","url":null,"abstract":"<p><p>A growing body of evidence suggests that low birth weight (LBW) offspring are associated with long-term structural and functional changes in cardiovascular and neuroendocrine systems. We tested the hypothesis that muscle metaboreflex activation produces exaggerated responses in cardiac autonomic tone (represented by heart rate variability ratio) and cutaneous vascular sympathetic tone (represented by plethysmography pulse wave amplitude) in LBW compared to normal birth weight (NBW) young adults. We recruited 23 LBW (18 females and five males) and 23 NBW (14 females and nine males) University of Zimbabwe students with neonatal clinical cards as proof of birth weight at term. Resting electrocardiogram, pulse waves, and blood pressures were recorded. Participants then underwent a static/isometric handgrip exercise until fatigue and a post-exercise circulatory arrest period of 2 minutes. We observed (results mean ± standard deviation) a greater mean increase in heart rate variability ratio from baseline to exercise for LBW compared to NBW individuals (1.015±1.034 versus [vs] 0.119±0.789, respectively; P<0.05). We also observed a greater mean decrease in plethysmography pulse wave amplitude from baseline to exercise (-1.32±1.064 vs -0.735±0.63; P<0.05) and from baseline to post-exercise circulatory arrest (-0.932±0.998 vs -0.389±0.563; P<0.05) for LBW compared to NBW individuals. We conclude that LBW may be associated with an exaggerated sympathetic discharge in response to muscle metaboreflex. </p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"8 ","pages":"37-42"},"PeriodicalIF":2.2,"publicationDate":"2015-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S76382","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33255958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Vitamin D status and hypertension: a review. 维生素D水平与高血压:综述。
IF 2.2 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2015-04-08 eCollection Date: 2015-01-01 DOI: 10.2147/IBPC.S49958
Liang Ke, Rebecca S Mason, Maina Kariuki, Elias Mpofu, Kaye E Brock

Vitamin D is a steroid prohormone synthesized in the skin following ultraviolet exposure and also achieved through supplemental or dietary intake. While there is strong evidence for its role in maintaining bone and muscle health, there has been recent debate regarding the role of vitamin D deficiency in hypertension based on conflicting epidemiological evidence. Thus, we conducted a scoping systematic literature review and meta-analysis of all observational studies published up to early 2014 in order to map trends in the evidence of this association. Mixed-effect meta-analysis was performed to pool risk estimates from ten prospective studies (n=58,262) (pooled risk for incident hypertension, relative risk [RR] =0.76 (0.63-0.90) for top vs bottom category of 25-hydroxyvitamin D [25OHD]) and from 19 cross-sectional studies (n=90,535) (odds ratio [OR] =0.79 (0.73-0.87)). Findings suggest that the better the assessed quality of the respective study design, the stronger the relationship between higher 25OHD levels and hypertension risk (RR =0.67 (0.51-0.88); OR =0.77 (0.72-0.89)). There was significant heterogeneity among the findings for both prospective and cross-sectional studies, but no evidence of publication bias was shown. There was no increased risk of hypertension when the participants were of older age or when they were vitamin D deficient. Younger females showed strong associations between high 25OHD levels and hypertension risk, especially in prospective studies (RR =0.36 (0.18-0.72); OR =0.62 (0.44-0.87)). Despite the accumulating evidence of a consistent link between vitamin D and blood pressure, these data are observational, so questions still remain in relation to the causality of this relationship. Further studies either combining existing raw data from available cohort studies or conducting further Mendelian analyses are needed to determine whether this represents a causal association. Large randomized controlled trials are also needed to determine whether vitamin supplementation may be beneficial in the prevention or the treatment of hypertension.

维生素D是一种类固醇激素原,在紫外线照射后在皮肤中合成,也可以通过补充或饮食摄入获得。虽然有强有力的证据表明维生素D在维持骨骼和肌肉健康方面的作用,但基于相互矛盾的流行病学证据,最近关于维生素D缺乏在高血压中的作用存在争议。因此,我们对截至2014年初发表的所有观察性研究进行了系统性文献综述和荟萃分析,以绘制这种关联证据的趋势图。对10项前瞻性研究(n=58,262)和19项横断面研究(n=90,535)(优势比[OR] =0.79(0.73-0.87))进行混合效应荟萃分析(25-羟基维生素D [25OHD]最高和最低类别的高血压事件的综合风险,相对风险[RR] =0.76(0.63-0.90))。研究结果表明,研究设计的评价质量越好,25OHD水平升高与高血压风险之间的关系越强(RR =0.67 (0.51-0.88);Or =0.77(0.72-0.89))。前瞻性和横断面研究的结果均存在显著的异质性,但未发现发表偏倚的证据。当参与者年龄较大或缺乏维生素D时,患高血压的风险并没有增加。年轻女性高25OHD水平与高血压风险之间存在强烈关联,尤其是在前瞻性研究中(RR =0.36 (0.18-0.72);Or =0.62(0.44-0.87))。尽管越来越多的证据表明维生素D和血压之间存在一致的联系,但这些数据是观察性的,因此这种关系的因果关系仍然存在问题。进一步的研究需要结合现有的原始数据,从现有的队列研究或进行进一步的孟德尔分析,以确定这是否代表因果关系。还需要进行大型随机对照试验,以确定补充维生素是否有助于预防或治疗高血压。
{"title":"Vitamin D status and hypertension: a review.","authors":"Liang Ke,&nbsp;Rebecca S Mason,&nbsp;Maina Kariuki,&nbsp;Elias Mpofu,&nbsp;Kaye E Brock","doi":"10.2147/IBPC.S49958","DOIUrl":"https://doi.org/10.2147/IBPC.S49958","url":null,"abstract":"<p><p>Vitamin D is a steroid prohormone synthesized in the skin following ultraviolet exposure and also achieved through supplemental or dietary intake. While there is strong evidence for its role in maintaining bone and muscle health, there has been recent debate regarding the role of vitamin D deficiency in hypertension based on conflicting epidemiological evidence. Thus, we conducted a scoping systematic literature review and meta-analysis of all observational studies published up to early 2014 in order to map trends in the evidence of this association. Mixed-effect meta-analysis was performed to pool risk estimates from ten prospective studies (n=58,262) (pooled risk for incident hypertension, relative risk [RR] =0.76 (0.63-0.90) for top vs bottom category of 25-hydroxyvitamin D [25OHD]) and from 19 cross-sectional studies (n=90,535) (odds ratio [OR] =0.79 (0.73-0.87)). Findings suggest that the better the assessed quality of the respective study design, the stronger the relationship between higher 25OHD levels and hypertension risk (RR =0.67 (0.51-0.88); OR =0.77 (0.72-0.89)). There was significant heterogeneity among the findings for both prospective and cross-sectional studies, but no evidence of publication bias was shown. There was no increased risk of hypertension when the participants were of older age or when they were vitamin D deficient. Younger females showed strong associations between high 25OHD levels and hypertension risk, especially in prospective studies (RR =0.36 (0.18-0.72); OR =0.62 (0.44-0.87)). Despite the accumulating evidence of a consistent link between vitamin D and blood pressure, these data are observational, so questions still remain in relation to the causality of this relationship. Further studies either combining existing raw data from available cohort studies or conducting further Mendelian analyses are needed to determine whether this represents a causal association. Large randomized controlled trials are also needed to determine whether vitamin supplementation may be beneficial in the prevention or the treatment of hypertension. </p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"8 ","pages":"13-35"},"PeriodicalIF":2.2,"publicationDate":"2015-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S49958","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33118640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 54
期刊
Integrated Blood Pressure Control
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1